Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734265 | 0.90 | LTA4H (0.38) | HRH2HRH1HRH3 | |
| SCHEMBL544481 | 0.90 | LTA4H (0.38) | HRH2HRH1HRH3 | |
| SCHEMBL6734147 | 0.90 | LTA4H (0.38) | HRH2HRH1HRH3 | |
| SCHEMBL10504563 | 0.90 | LTA4H (0.38) | HRH2HRH1HRH3 | |
| SCHEMBL10681465 | 0.90 | LTA4H (0.38) | HRH2HRH1HRH3 | |
| Hydrochloric Acid SCHEMBL14742972 | 0.87 | LTA4H (0.37) | HRH2HRH1HRH3 | |
| SCHEMBL11199066 | 0.84 | HRH3 (0.37) | NCF1HRH2HRH1HRH3 | |
| SCHEMBL855413 | 0.82 | HRH3 (0.36) | HRH2HRH1HRH3 | |
| SCHEMBL23828684 | 0.82 | HRH3 (0.35) | HRH2HRH1HRH3 | |
| SCHEMBL5188366 | 0.79 | ALOX15 (0.32) | ALOX15NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0021592-A1 | Phenylsulphonamide derivatives, a process for their preparation and their use as medicines | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1981-01-07 | — | — | EP | claimed |
| EP-0021580-A1 | Sulphonamide derivatives, a process for their preparation and their use as medicines | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1981-01-07 | — | — | EP | claimed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-7754919-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1940782-B1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| CN-101287702-A | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | CN | disclosed |
| EP-1940782-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045572-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045572-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
| US-4622331-A | AMINO SUBSTITUTED | Wuelfing, Johann A. (DE) | 1986-11-11 | — | — | US | disclosed |
| US-4436908-A | ANTIARRHYTHMIA AGENTS | Wuelfing, Johann A. (DE) | 1984-03-13 | — | — | US | disclosed |
| EP-0021580-B1 | SULPHONAMIDE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1983-12-14 | — | — | EP | disclosed |
| EP-0021592-B1 | PHENYLSULPHONAMIDE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1983-09-28 | — | — | EP | disclosed |
| US-4396622-A | Certain 1-(trifluoromethylphenyl sulfonamidoalkyl) azacycloalkanes and their use as anti-arrhythmic agents | Wuelfing, Johann A. (DE) | 1983-08-02 | — | — | US | disclosed |
| US-4372955-A | Anti-arrythmic sulphonamide compositions | Wuelfing, Johann A. (DE) | 1983-02-08 | — | — | US | disclosed |
| EP-0021592-A1 | Phenylsulphonamide derivatives, a process for their preparation and their use as medicines | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021580-A1 | Sulphonamide derivatives, a process for their preparation and their use as medicines | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, REV1 | ALOX15 1970/4885NCF1 437/4885HRH2 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.